555 related articles for article (PubMed ID: 32555510)
21. Increasing Gene Editing Efficiency for CRISPR-Cas9 by Small RNAs in Pluripotent Stem Cells.
Shahryari A; Moya N; Siehler J; Wang X; Burtscher I; Lickert H
CRISPR J; 2021 Aug; 4(4):491-501. PubMed ID: 34406042
[TBL] [Abstract][Full Text] [Related]
22. Genome Engineering for Stem Cell Transplantation.
Argani H
Exp Clin Transplant; 2019 Jan; 17(Suppl 1):31-37. PubMed ID: 30777520
[TBL] [Abstract][Full Text] [Related]
23. Efficient ssODN-Mediated Targeting by Avoiding Cellular Inhibitory RNAs through Precomplexed CRISPR-Cas9/sgRNA Ribonucleoprotein.
Kagita A; Lung MSY; Xu H; Kita Y; Sasakawa N; Iguchi T; Ono M; Wang XH; Gee P; Hotta A
Stem Cell Reports; 2021 Apr; 16(4):985-996. PubMed ID: 33711268
[TBL] [Abstract][Full Text] [Related]
24. Generation of Monoclonal iPSC Lines with Stable Cas9 Expression and High Cas9 Activity.
Liao JQ; Zhou G; Zhou Y
Methods Mol Biol; 2022; 2454():575-588. PubMed ID: 32567018
[TBL] [Abstract][Full Text] [Related]
25. Two Distinct Approaches for CRISPR-Cas9-Mediated Gene Editing in Cryptococcus neoformans and Related Species.
Wang P
mSphere; 2018 Jun; 3(3):. PubMed ID: 29898980
[No Abstract] [Full Text] [Related]
26. CRISPR Base Editing in Induced Pluripotent Stem Cells.
Chang YJ; Xu CL; Cui X; Bassuk AG; Mahajan VB; Tsai YT; Tsang SH
Methods Mol Biol; 2019; 2045():337-346. PubMed ID: 31250381
[TBL] [Abstract][Full Text] [Related]
27. Highly Efficient and Marker-free Genome Editing of Human Pluripotent Stem Cells by CRISPR-Cas9 RNP and AAV6 Donor-Mediated Homologous Recombination.
Martin RM; Ikeda K; Cromer MK; Uchida N; Nishimura T; Romano R; Tong AJ; Lemgart VT; Camarena J; Pavel-Dinu M; Sindhu C; Wiebking V; Vaidyanathan S; Dever DP; Bak RO; Laustsen A; Lesch BJ; Jakobsen MR; Sebastiano V; Nakauchi H; Porteus MH
Cell Stem Cell; 2019 May; 24(5):821-828.e5. PubMed ID: 31051134
[TBL] [Abstract][Full Text] [Related]
28. Efficient Generation and Correction of Mutations in Human iPS Cells Utilizing mRNAs of CRISPR Base Editors and Prime Editors.
Sürün D; Schneider A; Mircetic J; Neumann K; Lansing F; Paszkowski-Rogacz M; Hänchen V; Lee-Kirsch MA; Buchholz F
Genes (Basel); 2020 May; 11(5):. PubMed ID: 32384610
[TBL] [Abstract][Full Text] [Related]
29. Efficient manipulation of gene dosage in human iPSCs using CRISPR/Cas9 nickases.
Ye T; Duan Y; Tsang HWS; Xu H; Chen Y; Cao H; Chen Y; Fu AKY; Ip NY
Commun Biol; 2021 Feb; 4(1):195. PubMed ID: 33580208
[TBL] [Abstract][Full Text] [Related]
30. CRISPR/Cas9-mediated knockout of clinically relevant alloantigenes in human primary T cells.
Kamali E; Rahbarizadeh F; Hojati Z; Frödin M
BMC Biotechnol; 2021 Jan; 21(1):9. PubMed ID: 33514392
[TBL] [Abstract][Full Text] [Related]
31. Robust genome editing via modRNA-based Cas9 or base editor in human pluripotent stem cells.
Haideri T; Howells A; Jiang Y; Yang J; Bao X; Lian XL
Cell Rep Methods; 2022 Sep; 2(9):100290. PubMed ID: 36160051
[TBL] [Abstract][Full Text] [Related]
32. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
33. Genome-wide CRISPR/Cas9-knockout in human induced Pluripotent Stem Cell (iPSC)-derived macrophages.
Navarro-Guerrero E; Tay C; Whalley JP; Cowley SA; Davies B; Knight JC; Ebner D
Sci Rep; 2021 Feb; 11(1):4245. PubMed ID: 33608581
[TBL] [Abstract][Full Text] [Related]
34. Genome editing using CRISPR/Cas9 to treat hereditary hematological disorders.
Chen Y; Wen R; Yang Z; Chen Z
Gene Ther; 2022 May; 29(5):207-216. PubMed ID: 33750926
[TBL] [Abstract][Full Text] [Related]
35. CRISPR/Cas9-Based Safe-Harbor Gene Editing in Rhesus iPSCs.
Yada RC; Ostrominski JW; Tunc I; Hong SG; Zou J; Dunbar CE
Curr Protoc Stem Cell Biol; 2017 Nov; 43():5A.11.1-5A.11.14. PubMed ID: 29140568
[TBL] [Abstract][Full Text] [Related]
36. CRISPR-Cas9-mediated pinpoint microbial genome editing aided by target-mismatched sgRNAs.
Lee HJ; Kim HJ; Lee SJ
Genome Res; 2020 May; 30(5):768-775. PubMed ID: 32327447
[TBL] [Abstract][Full Text] [Related]
37. Successful correction of factor V deficiency of patient-derived iPSCs by CRISPR/Cas9-mediated gene editing.
Nakamura T; Morishige S; Ozawa H; Kuboyama K; Yamasaki Y; Oya S; Yamaguchi M; Aoyama K; Seki R; Mouri F; Osaki K; Okamura T; Mizuno S; Nagafuji K
Haemophilia; 2020 Sep; 26(5):826-833. PubMed ID: 32700411
[TBL] [Abstract][Full Text] [Related]
38. The Combination of CRISPR/Cas9 and iPSC Technologies in the Gene Therapy of Human β-thalassemia in Mice.
Ou Z; Niu X; He W; Chen Y; Song B; Xian Y; Fan D; Tang D; Sun X
Sci Rep; 2016 Sep; 6():32463. PubMed ID: 27581487
[TBL] [Abstract][Full Text] [Related]
39. CRISPR/Cas9-based Targeted Genome Editing for the Development of Monogenic Diseases Models with Human Pluripotent Stem Cells.
Gupta N; Susa K; Yoda Y; Bonventre JV; Valerius MT; Morizane R
Curr Protoc Stem Cell Biol; 2018 May; 45(1):e50. PubMed ID: 30040245
[TBL] [Abstract][Full Text] [Related]
40. Cell-type-specific genome editing with a microRNA-responsive CRISPR-Cas9 switch.
Hirosawa M; Fujita Y; Parr CJC; Hayashi K; Kashida S; Hotta A; Woltjen K; Saito H
Nucleic Acids Res; 2017 Jul; 45(13):e118. PubMed ID: 28525578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
